BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 1735846)

  • 1. Pulmonary mechanics and energetics in preterm infants who had respiratory distress syndrome treated with synthetic surfactant.
    Bhutani VK; Abbasi S; Long WA; Gerdes JS
    J Pediatr; 1992 Feb; 120(2 Pt 2):S18-24. PubMed ID: 1735846
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term pulmonary consequences of respiratory distress syndrome in preterm infants treated with exogenous surfactant.
    Abbasi S; Bhutani VK; Gerdes JS
    J Pediatr; 1993 Mar; 122(3):446-52. PubMed ID: 8441104
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pulmonary mechanics in ventilated preterm infants with respiratory distress syndrome after exogenous surfactant administration: a comparison between two surfactant preparations.
    Choukroun ML; Llanas B; Apere H; Fayon M; Galperine RI; Guenard H; Demarquez JL
    Pediatr Pulmonol; 1994 Nov; 18(5):273-8. PubMed ID: 7898964
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pulmonary mechanics in premature infants one month after treatment with synthetic surfactant.
    Goldman SL; Bosque E; McCann E; Lewis K
    J Pediatr; 1992 Feb; 120(2 Pt 2):S25-8. PubMed ID: 1735847
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Postnatal changes in pulmonary mechanics and energetics of infants with respiratory distress syndrome following surfactant treatment.
    Bhutani VK; Bowen FW; Sivieri EM
    Biol Neonate; 2005; 87(4):323-31. PubMed ID: 15985755
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A controlled trial of synthetic surfactant in infants weighing 1250 g or more with respiratory distress syndrome. The American Exosurf Neonatal Study Group I, and the Canadian Exosurf Neonatal Study Group.
    Long W; Corbet A; Cotton R; Courtney S; McGuiness G; Walter D; Watts J; Smyth J; Bard H; Chernick V
    N Engl J Med; 1991 Dec; 325(24):1696-703. PubMed ID: 1944470
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A multicenter randomized masked comparison trial of synthetic surfactant versus calf lung surfactant extract in the prevention of neonatal respiratory distress syndrome.
    Hudak ML; Martin DJ; Egan EA; Matteson EJ; Cummings NJ; Jung AL; Kimberlin LV; Auten RL; Rosenberg AA; Asselin JM; Belcastro MR; Donohue PK; Hamm CR; Jansen RD; Brody AS; Riddlesberger MM; Montgomery P
    Pediatrics; 1997 Jul; 100(1):39-50. PubMed ID: 9200358
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Static respiratory compliance in the newborn. III: Early changes after exogenous surfactant treatment.
    Stenson BJ; Glover RM; Parry GJ; Wilkie RA; Laing IA; Tarnow-Mordi WO
    Arch Dis Child Fetal Neonatal Ed; 1994 Jan; 70(1):F19-24. PubMed ID: 8117122
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A multicenter, randomized trial comparing synthetic surfactant with modified bovine surfactant extract in the treatment of neonatal respiratory distress syndrome. Vermont-Oxford Neonatal Network.
    Pediatrics; 1996 Jan; 97(1):1-6. PubMed ID: 8545199
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative trial of artificial and natural surfactants in the treatment of respiratory distress syndrome of prematurity: experiences in a developing country.
    da Costa DE; Pai MG; Al Khusaiby SM
    Pediatr Pulmonol; 1999 May; 27(5):312-7. PubMed ID: 10344709
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Use of Exosurf Neonatal, a synthetic surfactant, in the treatment of respiratory distress syndrome in the newborn].
    Mikhel'sonVA ; Grebennikov VA; Belaĭ VA; Everstova TN
    Anesteziol Reanimatol; 1995; (1):4-7. PubMed ID: 7605034
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Modified bovine surfactant (Survanta) versus a protein-free surfactant (Exosurf) in the treatment of respiratory distress syndrome in preterm infants: a pilot study.
    Sehgal SS; Ewing CK; Richards T; Taeusch HW
    J Natl Med Assoc; 1994 Jan; 86(1):46-52. PubMed ID: 8151722
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A multicenter randomized trial comparing two surfactants for the treatment of neonatal respiratory distress syndrome. National Institute of Child Health and Human Development Neonatal Research Network.
    Horbar JD; Wright LL; Soll RF; Wright EC; Fanaroff AA; Korones SB; Shankaran S; Oh W; Fletcher BD; Bauer CR
    J Pediatr; 1993 Nov; 123(5):757-66. PubMed ID: 8229487
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A multicenter randomized, masked comparison trial of natural versus synthetic surfactant for the treatment of respiratory distress syndrome.
    Hudak ML; Farrell EE; Rosenberg AA; Jung AL; Auten RL; Durand DJ; Horgan MJ; Buckwald S; Belcastro MR; Donohue PK; Carrion V; Maniscalco WW; Balsan MJ; Torres BA; Miller RR; Jansen RD; Graeber JE; Laskay KM; Matteson EJ; Egan EA; Brody AS; Martin DJ; Riddlesberger MM; Montgomery P
    J Pediatr; 1996 Mar; 128(3):396-406. PubMed ID: 8774514
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Colfosceril palmitate. A review of the therapeutic efficacy and clinical tolerability of a synthetic surfactant preparation (Exosurf Neonatal) in neonatal respiratory distress syndrome.
    Dechant KL; Faulds D
    Drugs; 1991 Nov; 42(5):877-94. PubMed ID: 1723378
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Delayed compliance increase in infants with respiratory distress syndrome following synthetic surfactant.
    Armsby DH; Bellon G; Carlisle K; Rector D; Baldwin R; Long W; Stevenson DK; Ariagno RL
    Pediatr Pulmonol; 1992 Dec; 14(4):206-13. PubMed ID: 1484754
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lung mechanics and gas exchange in ventilated preterm infants during treatment of hyaline membrane disease with multiple doses of artificial surfactant (Exosurf).
    Pfenninger J; Aebi C; Bachmann D; Wagner BP
    Pediatr Pulmonol; 1992 Sep; 14(1):10-5. PubMed ID: 1437337
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Double-blind, randomized, placebo-controlled Canadian multicenter trial of two doses of synthetic surfactant or air placebo in 224 infants weighing 500 to 749 grams with respiratory distress syndrome. Canadian Exosurf Neonatal Study Group.
    Smyth J; Allen A; MacMurray B; Peliowski A; Sankaran K; Volberg F; Shukla A; Long W
    J Pediatr; 1995 May; 126(5 Pt 2):S81-9. PubMed ID: 7745516
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mucus rheology and transport in neonatal respiratory distress syndrome and the effect of surfactant therapy.
    Rubin BK; Ramirez O; King M
    Chest; 1992 Apr; 101(4):1080-5. PubMed ID: 1555424
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of two rescue doses of a synthetic surfactant on mortality rate and survival without bronchopulmonary dysplasia in 700- to 1350-gram infants with respiratory distress syndrome. The American Exosurf Neonatal Study Group I.
    Long W; Thompson T; Sundell H; Schumacher R; Volberg F; Guthrie R
    J Pediatr; 1991 Apr; 118(4 Pt 1):595-605. PubMed ID: 2007938
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.